Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated...

Area of Science:

• Pediatric Oncology
• Hematologic Malignancies
• Clinical Trial Design

Background:

• Infants with acute lymphoblastic leukemia (ALL) face a poor prognosis, with most treatment failures occurring within 6-9 months due to relapse.
• High early mortality rates in infants with ALL necessitate improved treatment strategies.

Purpose of the Study:

• To evaluate the impact of intensified early treatment on outcomes for infants diagnosed with ALL.
• To reduce early deaths and improve survival rates in infant ALL patients through modified induction therapy.

Main Methods:

• The Children's Oncology Group P9407 study initially tested intensified treatment for infant ALL.
• Induction therapy was amended three times due to significant early deaths (<90 days).
• Cohort 3 (n=141) received prednisone instead of dexamethasone, short-infusion daunorubicin, and enhanced supportive care, compared to Cohorts 1+2 (n=68).

Main Results:

• Early deaths decreased significantly from 25% in Cohorts 1+2 to 5.7% in Cohort 3 (P < 0.0001).
• This reduction was observed in both younger (≤90 days) and older (>90 days) infants at diagnosis.
• Infections were less common in Cohort 3, indicating improved supportive care.

Conclusions:

• Substituting prednisone for dexamethasone and using shorter daunorubicin infusions significantly reduced early morbidity and mortality in infants with ALL.
• Enhanced supportive care measures further contributed to improved outcomes.
• These modifications represent a critical advancement in managing infant ALL.